LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations

SCHOFIELD, Wis., Nov. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.

In the article entitled, "Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question," the authors warn physicians not to "recommend prolonged or frequent use of over-the-counter (OTC) pain medications for headache." The American Headache Society (AHS) article recommended that OTC headache pain relievers should not be used more than twice a week to avoid the incidence of "medication overuse headache," especially when the medications contain caffeine. The article goes on to cite the dangers of liver damage caused by the overuse of acetaminophen and gastrointestinal bleeding caused by overuse of nonsteroidal anti-inflammatory drugs.

"Having a product like LipiGesic M that does not produce 'medication overuse headache' is important in light of the latest report published by the AHS," said Russell Mitchell, CEO of PuraMed BioScience. "There have been no reported occurrences of LipiGesic M causing a rebound headache no matter how frequently a person uses it. LipiGesic M's patented formulation of feverfew and ginger also has not been shown to cause liver damage, stomach bleeding, or other adverse side effects."

When writing the "Choosing Wisely in Headache Medicine: ..." article published in the November/December 2013 issue of Headache, the authors asked AHS members to suggest tests, procedures, or treatments in headache medicine that were commonly overused or misused. The five suggestions selected "were associated with poor patient outcomes, low value care or documented overuse or misuse," the study said.

"LipiGesic M is not like the pain relievers that are cited in the study," said Mitchell. "Based on the results of our clinical trial, LipiGesic M performs more like a prescription migraine medication than an OTC migraine formulation, but without the unwanted side effects associated with either product category."

This fact was also stated in Advances in Drug Development for Acute Migraine, an article published in Drugs medical journal in December 2012. Speaking of LipiGesic M, the authors, including headache expert Dr. Roger Cady, said, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."

The Cleveland Clinic website also lists many medications that can cause rebound headache. The list includes: "aspirin, sinus relief medications, acetaminophen, nonsteroidal anti-inflammatory medications (NSAIDs), sedatives for sleep, codeine and prescription narcotics, and over-the-counter combination headache remedies containing caffeine (such as Anacin®, Excedrin®, Bayer Select®, and others)." http://my.clevelandclinic.org/disorders/Headaches/hic_Rebound_Headaches.aspx

"Recently there have been an increased number of Food and Drug Administration safety warnings associated with acetaminophen and other OTC pain medications," said Mitchell. "People forget that many OTC medications were only available as prescriptions when they were first introduced. That's why it is personally gratifying to offer a highly effective treatment for acute migraine that does not cause the harmful side effects mentioned by the report."

Currently, PuraMed BioScience has 68,702,155 shares outstanding.

About PuraMed BioScience, Inc.:
PuraMed BioScience has completed a double blind placebo clinical trial for its leading product, LipiGesic® M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract. LipiGesic® M has national distribution and is available nationwide in some of the largest chain drug stores in the United States.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Patricia McMurtrie
715-571-4910
patricia@PuramedBioScience.com
www.PuramedBioScience.com

SOURCE PuraMed BioScience, Inc.



RELATED LINKS
http://www.puramedbioscience.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.